Health By Usha Lee McFarling He wants to sell you a $300 ‘fasting diet’ to prolong your life. It might not be as crazy as it sounds
Health By Nicholas Florko See one woman’s complicated, costly journey to a Canadian strip mall pharmacy — all for cheaper insulin
Politics By Nicholas Florko ‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around
Health By Lev Facher It’s the insulin, stupid: How drug pricing’s simplest case study became a top issue for 2020 Democrats
First Opinion By Tessa Copp, Kirsten McCaffery, Jenny Doust, Jolyn Hersch, and Jesse Jansen Overdiagnosis and disease labels: the case of polycystic ovary syndrome
First Opinion By Lorena Alarcon-Casas Wright Time in range: a new way for people with diabetes to monitor blood sugar
Politics By Nicholas Florko Quinn Nystrom is betting a platform laser-focused on high insulin prices will propel her to Congress
Politics By Nicholas Florko Trump claims his policies made insulin ‘so cheap, it’s like water.’ But for most people, it costs just as much as before
Politics By Nicholas Florko Drug makers sue to block Minnesota law making it cheaper to get insulin in emergencies
Health By Meghana Keshavan As wave of Covid-19 cases crashes, a surge in other health conditions looms
Pharmalot By Ed Silverman Pharmalittle: WHO sets goals for distributing Covid-19 treatments; new warnings urged on diabetes drugs
Biotech By Jonathan Chan A Chinese drug maker scores a big clinical trial win with a novel diabetes therapy
Pharmalot By Ed Silverman Pharmalittle: U.S. Chamber wants transparency around Covid-19 vaccines; EU to pump billions into vaccine deals
Pharmalot By Ed Silverman Pharmalittle: Glaxo aims for 1 billion doses of a Covid-19 vaccine booster; Pence aide holds lots of pharma stocks
Health Tech By Casey Ross In fading steel towns, chronically ill patients hope video visits stay after the pandemic goes
Politics By Nicholas Florko After a hard-won political fight, this state expanded access to insulin. Can others follow its lead?
Pharmalot By Ed Silverman Novo Nordisk becomes latest insulin maker seeking to foster goodwill amid Covid-19
Health Tech By Erin Brodwin With Covid-19 delaying routine care, chronic disease startups brace for a slew of complications
Politics By Nicholas Florko Will Trump’s new plan to cap insulin costs in Medicare actually save seniors much money? It’s complicated
Pharmalot By Ed Silverman FDA petitioned to recall batches of metformin diabetes pill over a possible carcinogen
Politics By STAT staff Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation
Pharmalot By Ed Silverman Years later, raw clinical trial data tells us the extent of Avandia’s heart risks
Politics By Nicholas Florko More than a dozen Democrats are bringing people with sky-high insulin bills to the State of the Union
Health Tech By Erin Brodwin and Matthew Herper Verily’s top health leaders: We’re ‘trying to solve problems that many of us have lived’
Health Tech By Rebecca Robbins Eyeing more data, Livongo will integrate continuous glucose monitor into diabetes coaching program